Cargando…
Comparative quantitative systems pharmacology modeling of anti-PCSK9 therapeutic modalities in hypercholesterolemia
Since the discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) as an attractive target in the treatment of hypercholesterolemia, multiple anti-PCSK9 therapeutic modalities have been pursued in drug development. The objective of this research is to set the stage for the quantitative ben...
Autores principales: | Sokolov, Victor, Helmlinger, Gabriel, Nilsson, Catarina, Zhudenkov, Kirill, Skrtic, Stanko, Hamrén, Bengt, Peskov, Kirill, Hurt-Camejo, Eva, Jansson-Löfmark, Rasmus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society for Biochemistry and Molecular Biology
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718444/ https://www.ncbi.nlm.nih.gov/pubmed/31292220 http://dx.doi.org/10.1194/jlr.M092486 |
Ejemplares similares
-
Thyroid hormone reduces PCSK9 and stimulates bile acid synthesis in humans
por: Bonde, Ylva, et al.
Publicado: (2014) -
Use of next-generation sequencing to detect LDLR gene copy number variation in familial hypercholesterolemia
por: Iacocca, Michael A., et al.
Publicado: (2017) -
Interpretation of metabolic memory phenomenon using a physiological systems model: What drives oxidative stress following glucose normalization?
por: Voronova, Veronika, et al.
Publicado: (2017) -
Longitudinal FEV(1) and Exacerbation Risk in COPD: Quantifying the Association Using Joint Modelling
por: Zhudenkov, Kirill, et al.
Publicado: (2021) -
A case‐study of model‐informed drug development of a novel PCSK9 anti sense oligonucleotide. Part 1: First time in man to phase II
por: Knöchel, Jane, et al.
Publicado: (2022)